← Back to all trials
Terminated
NCT05255601
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease
Sex: All
Ages: N/A – 30 Years
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 5
Sponsor: Bristol-Myers Squibb
Location: Local Institution - 0077 Birmingham Alabama
Summary
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria:
* Participants with pathologically confirmed high-risk R/R cHL, after non-response to or failure of 1or more lines of standard therapy.
* Participants with pathologically confirmed R/R NHL after non-response to or failure of 1or more lines of standard therapy, including, but not limited to, R/R primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).
* Participants with pathologically confirmed R/R NHL after non-response to or failure of 2 or more lines of standard therapy, including Burkitt lymphoma (blast count \
Source: ClinicalTrials.gov (NCT05255601). StuddyBuddy aggregates publicly available trial information.
